Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors

• Titel: Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors
• Titelzusatz: guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
• Mitwirkende: Rieger, Christina [VerfasserIn]
• Mitwirkende: Buchheidt, Dieter [VerfasserIn]
• Mitwirkende: Egerer, Gerlinde [VerfasserIn]
• Mitwirkende: Giesen, Nicola [VerfasserIn]
• Körperschaft: Deutsche Gesellschaft für Hämatologie und Onkologie / Arbeitsgemeinschaft Infektiologie [VerfasserIn]
• Verf.angabe: C. T. Rieger, B. Liss, S. Mellinghoff, D. Buchheidt, O. A. Cornely, G. Egerer, W. J. Heinz, M. Hentrich, G. Maschmeyer, K. Mayer, M. Sandherr, G. Silling, A. Ullmann, M. J. G. T. Vehreschild, M. von Lilienfeld-Toal, H. H. Wolf, N. Lehners
• E-Jahr: 2018
• Jahr: 24 April 2018
• Umfang: 12 S.
• Fussnoten: Gesehen am 14.02.2020
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1990
• Jahr Quelle: 2018
• Band/Heft Quelle: 29(2018), 6, Seite 1354-1365
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdy117
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anti-infective vaccination
• Sach-SW: autologous stem cell transplantation
• Sach-SW: cancer
• Sach-SW: immunosuppression
• Sach-SW: infection
• K10plus-PPN: 1690035412

Abstract

Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.